ArticleCirculation. Cardiovascular quality and outcomes2024
Cost of Cardiovascular Disease Event and Cardiovascular Disease Treatment-Related Complication Hospitalizations in the United States.
Article in Circulation. Cardiovascular quality and outcomes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effect of exercise on kidney-relevant biomarkers in the general population: a systematic review and meta-analysis.BMJ open · 2025Pooled it
- Cost-Effectiveness of Bempedoic Acid in High Cardiovascular Risk Patients with Statin Intolerance: An Analysis of the CLEAR Outcomes Trial.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026Trial
- Predictive Modeling of Coronary Artery Disease Using Color Fundus Photography-Based Features of Retinal Vasculature.Ophthalmology and therapy · 2026Article
- Cost-Effectiveness of Endovascular vs Open Surgery for Chronic Limb-Threatening Ischemia.JAMA network open · 2026Article
- Cost-effectiveness of contingency management for methamphetamine use disorder: A model-based analysis.Addiction (Abingdon, England) · 2026Article
- Tailored Text Messaging Intervention to Improve Self-Care in Patients With Heart Failure (Text4HF): Protocol for a Pilot Randomized Controlled Trial.JMIR research protocols · 2026Article
- The Impact of Hearing Loss on Hospitalizations Among US Adults with Heart Failure.Journal of general internal medicine · 2026Article
- Multicenter, randomized controlled study evaluating percutaneous and non-fluoroscopic procedure of atrial septal defects-study protocol of the PANASD randomized controlled trial.American heart journal plus : cardiology research and practice · 2026Article
- The value of retinal microvascular features in predicting risk stratification and long-term prognosis of patients with acute coronary syndrome.BMC ophthalmology · 2026Article
- Economic modeling of polygenic risk prediction of coronary artery disease in childhood.NPJ cardiovascular health · 2026Article
- Application of Telemedicine and Artificial Intelligence in Outpatient Cardiology Care: TeleAI-CVD Study (Design).Diagnostics (Basel, Switzerland) · 2026Article
- Thirty-Day Readmission Risk Among Adults Hospitalized for Heart Failure or Acute Myocardial Infarction With and Without HIV.Open forum infectious diseases · 2025Article
- The Rise of Optical Coherent Tomography in Intracoronary Imaging: An Overview of Current Technology, Limitations, and Future Perspectives.Reviews in cardiovascular medicine · 2025Review
- Retinal Imaging as a Window into Cardiovascular Health: Towards Harnessing Retinal Analytics for Precision Cardiovascular Medicine.Journal of cardiovascular development and disease · 2025Review
- Economic and equity evaluation of age restrictions on over-the-counter diet pills and muscle-building supplements.Health affairs scholar · 2025Article
- The Impact of Comorbid Sleep-Disordered Breathing on Hospitalization Risk Related to Diabetes and Atherosclerotic Disease: A Retrospective Cohort Analysis.Journal of clinical medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCardiovascular disease (CVD) is among the costliest conditions in the United States, and cost-effectiveness analyses can be used to assess economic impact and prioritize CVD treatments. We aimed to develop standardized, nationally representative CVD events and selected possible CVD treatment-related complication hospitalization costs for use in cost-effectiveness analyses.
methodsNationally representative costs were derived using publicly available inpatient hospital discharge data from the 2012-2018 National Inpatient Sample. Events were identified using the principal
resultsThe annual mean number of hospital discharges among CVD events was the highest for heart failure (1 087 000 per year) and cerebrovascular disease (800 600 per year). The mean cost per hospital discharge was the highest for peripheral vascular disease ($33 700 [95% CI, $33 300-$34 000]) and ventricular tachycardia/ventricular fibrillation ($32 500 [95% CI, $32 100-$32 900]). Hospitalizations contributing the most to annual US health care costs were heart failure ($19 500 [95% CI, $19 300-$19 800] million) and acute myocardial infarction ($18 300, [95% CI, $18 200-$18 500] million). Acute kidney injury was the most frequent possible treatment complication (515 000 per year), and bradycardia had the highest mean hospitalization costs ($17 400 [95% CI, $17 200-$17 500]).
conclusionsThe hospitalization cost estimates and statistical code reported in the current study have the potential to increase transparency and comparability of cost-effectiveness analyses for CVD in the United States.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.